Connect with us

Published

on

Illustration by Elham Ataeiazar

Artificial intelligence is scary to a lot of people, even within the tech world. Just look at how industry insiders have co-opted a tentacled monster called a shoggoth as a semi-tongue-in-cheek symbol for their rapidly advancing work.

But their online memes and references to that creature — which originated in influential late author H.P. Lovecraft’s novella “At the Mountains of Madness” — aren’t quite perfect, according to the world’s leading Lovecraft scholar, S.T. Joshi.

related investing news

Cramer lists reasons to book some profits in this lofty market. 'You only need to get rich once'

CNBC Investing Club

If anyone knows Lovecraft and his wretched menagerie, which includes the ever-popular Cthulhu, it’s Joshi. He’s edited reams of Lovecraft collections, contributed scores of essays about the author and written more than a dozen books about him, including the monumental two-part biography “I Am Providence.”

So, after The New York Times recently published a piece from tech columnist Kevin Roose explaining that the shoggoth had caught on as “the most important meme in A.I.,” CNBC reached out to Joshi to get his take — and find out what he thought Lovecraft would say about the squirmy homage from the tech world.

“While I’m sure Lovecraft would be grateful (and amused) by the application of his creation to AI, the parallels are not very exact,” Joshi wrote. “Or, I should say, it appears that AI creators aren’t entirely accurate in their understanding of the shoggoth.”

Read more: How to talk about AI like an insider

First of all, it’s “shoggoth,” not “Shoggoth,” Joshi said. The capitalized version of the word, as it’s spelled in the Times article, has indeed appeared in many editions of “At the Mountains of Madness,” which was first published in “Astounding Stories” in 1936, the year before Lovecraft died at age 46. But decades ago, Joshi found that Lovecraft himself made it lowercase in his manuscript and typescript of the science fiction/horror tale set in Antarctica.

“It is a species name, not a proper name,” Joshi wrote in an email to CNBC.

But that’s a minor quibble. There are bigger thematic things to consider.

Workers and others in the generative-AI field use the shoggoth meme, which often appears as a squiggly cartoon festooned with eyes and appendages, to acknowledge the mysterious, at-times frightening potential of the technology. “That some A.I. insiders refer to their creations as Lovecraftian horrors, even as a joke, is unusual by historical standards,” Roose wrote in his Times column.

The recent advancement of generative AI has already provoked references to science fiction classics such as “The Terminator” and “The Matrix,” or Harlan Ellison’s chilling science fiction story “I Have No Mouth, and I Must Scream,” all of which portray sinister artificial intelligence wiping out most of humanity.

Bringing Lovecraft’s cosmic horrors into the mix might seem excessive at this point, even as the technology creates uncanny things. For instance, a recent fake Toronto Blue Jays ad, created by a TSN producer who used text-to-video AI tech, is packed with horrifying images such as people feasting on each other’s hot dog tentacles.

The shoggoth meme’s creator, known by the Twitter handle @TetraspaceWest, said the inspiration came about because Lovecraft’s monsters are “indifferent and their priorities are totally alien to us and don’t involve humans, which is what I think will be true about possible future powerful A.I.”

Astounding Stories – February 1936 (Street & Smith) – “At the Mountains of Madness” by H. P. Lovecraft. Artist Howard V. Brown, 1936

Pierce Archive LLC | Buyenlarge | Getty Images

The meme also tries to put a happy face on the shoggoth — literally — as it usually depicts the monster sporting a smile emoji on a tentacle. That’s in reference to efforts to train language models to be nice, according to the Times. It also reads like a commentary on how futile and absurd it might be to try.

Lovecraft’s shoggoths probably wouldn’t entertain the idea of sending a friendly signal, and, in the story, they certainly aren’t indifferent to their creators, whom they try to usurp.

While artificial intelligence is based in machines, the monsters in the novella are organically bred slave creatures that develop brains and their own will, Joshi pointed out. Lovecraft describes a shoggoth as a “column of foetid black iridescence” consisting of “protoplasmic bubbles, faintly self-luminous, and with myriads of temporary eyes forming and unforming as pustules of greenish light.”

A big concern among people who fear AI is that the programs will someday become more intelligent than humans and take over. There is no parallel event in Lovecraft’s story. The shoggoths don’t end up surpassing their masters, the ancient Old Ones, “in intelligence or any other capacity,” Joshi writes. “Lovecraft clearly states otherwise.”

That’s not to say the meme totally misses the mark.

In the story, shoggoths rise up against the Old Ones in a series of slave revolts that surely contribute to the collapse of the Old Ones’ society, Joshi notes. The AI anxiety that inspired comparisons to the cartoon monster image certainly resonates with the ultimate fate of that society.

“So the general metaphor of an artificial creation overwhelming its creator does have some sort of parallel to AI (or the fears of what AI might do in the future), but it’s a fairly inexact parallel,” Joshi wrote.

But even this imperfect metaphor pairs well with what happens in Lovecraft’s story, which describes a once-grand civilization that had too many problems to fix.

In our world — a world beset by toxic wildfire smoke and water shortages, violent insurrections in democracies, and the most military combat in Europe since World War II — AI is just part of a whole. There’s a lot of hype and confusion around it, as well as positive potential. There are also real concerns, namely in how AI could act as an accelerant for bigotry and extremism, or as an engine for misinformation, or as a job killer.

In the novella, the Old Ones fall prey to a variety of threats, including attacks from rival entities who come from outer space. The story ends with insinuations of even greater mind-shattering horrors that lay beyond the mountains of madness.

In reality, humans could well scale those terrible heights with the help of AI, but only if we let it happen. Maybe we should be the ones wearing the smiley faces.

Continue Reading

Technology

Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million

Published

on

By

Anne Wojcicki has a new offer to take 23andMe private, this time for .7 million

Anne Wojcicki attends the WSJ Magazine Style & Tech Dinner in Atherton, California, on March 15, 2023.

Kelly Sullivan | Getty Images Entertainment | Getty Images

23andMe CEO Anne Wojcicki and New Mountain Capital have submitted a proposal to take the embattled genetic testing company private, according to a Friday filing with the U.S. Securities and Exchange Commission.

Wojcicki and New Mountain have offered to acquire all of 23andMe’s outstanding shares in cash for $2.53 per share, or an equity value of approximately $74.7 million. The company’s stock closed at $2.42 on Friday with a market cap of about $65 million.

The offer comes after a turbulent year for 23andMe, with the stock losing more than 80% of its value in 2024. In January, the company announced plans to explore strategic alternatives, which could include a sale of the company or its assets, a restructuring or a business combination. 

Read more CNBC tech news

23andMe has a special committee of independent directors in place to evaluate potential paths forward. The company appointed three new independent directors to its board in October after all seven of its previous directors abruptly resigned the prior month. The special committee has to approve Wojcicki and New Mountain’s proposal.

“We believe that our Proposal provides compelling value and immediate liquidity to the Company’s public stockholders,” Wojcicki and Matthew Holt, managing director and president of private equity at New Mountain, wrote in a letter to the special committee on Thursday.

Wojcicki previously submitted a proposal to take the company private for 40 cents per share in July, but it was rejected by the special committee, in part because the members said it lacked committed financing and did not provide a premium to the closing price at the time.

Wojcicki and New Mountain are willing to provide secured debt financing to fund 23andMe’s operations through the transaction’s closing, the filing said. New Mountain is based in New York and has $55 billion of assets under management, according to its website.

23andMe declined to comment.

WATCH: The rise and fall of 23andMe

The rise and fall of 23andMe

Continue Reading

Technology

Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage

Published

on

By

Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage

Hims & Hers

Shares of Hims & Hers Health tumbled more than 23% on Friday after the U.S. Food and Drug Administration announced that the shortage of semaglutide injection products has been resolved.

Semaglutide is the active ingredient in Novo Nordisk‘s blockbuster weight loss drug Wegovy and diabetes treatment Ozempic. Those medications are part of a class of drugs called GLP-1s, and demand for the treatments has exploded in recent years. As a result, digital health companies such as Hims & Hers have been prescribing compounded semaglutide as an alternative for patients who are navigating volatile supply hurdles and insurance obstacles.

Compounded drugs are custom-made alternatives to brand-name drugs designed to meet a specific patient’s needs, and compounders are allowed to produce them when brand-name treatments are in shortage. The FDA doesn’t review the safety and efficacy of compounded products.

Hims & Hers began offering compounded semaglutide to patients in May, and it owns compounding pharmacies that produce the medications.

Compounded medications are typically much cheaper than their branded counterparts. Hims & Hers sells compounded semaglutide for less than $200 per month, while Ozempic and Wegovy both cost around $1,000 per month without insurance.

Read more CNBC tech news

The FDA said Friday that it will start taking action against compounders for violations in the next 60 to 90 days, depending on the type of facility, in order to “avoid unnecessary disruption to patient treatment.”

“Now that the FDA has determined the drug shortage for semaglutide has been resolved, we will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO Andrew Dudum posted Friday on X. “We’re also closely monitoring potential future shortages, as Novo Nordisk stated two weeks ago that it would continue to have ‘capacity limitations’ and ‘expected continued periodic supply constraints and related drug shortage notifications.'”

Him & Hers’ weight loss offerings have been a massive hit with investors. Shares of the company climbed more than 200% last year, and the stock is already up more than 100% this year despite Friday’s move.

Even before it added compounded GLP-1s to its portfolio, the company said in its 2023 fourth-quarter earnings call that it expects its weight loss program to bring in more than $100 million in revenue by the end of 2025.

Despite the turbulent regulatory landscape, Hims & Hers has showed no signs of slowing down.

On Friday, the company announced it has acquired a U.S.-based peptide facility that will “further verticalize the company’s long-term ability to deliver personalized medications.” Hims & Hers will explore advances across metabolic optimization, recovery science, biological resistances, cognitive performance and preventative health through the acquisition, the company said.

That move comes just days after Hims & Hers also bought Trybe Labs, the New Jersey-based at-home lab testing facility. Trybe Labs will allow Hims & Hers to perform at-home blood draws and more comprehensive pretreatment testing.

Hims & Hers did not disclose the terms of either deal.

WATCH: Hims & Hers Super Bowl ad sparks controversy

Hims & Hers Super Bowl ad sparks controversy

Continue Reading

Technology

Tesla recalls more than 375,000 vehicles in U.S. due to failing power-assisted steering systems

Published

on

By

Tesla recalls more than 375,000 vehicles in U.S. due to failing power-assisted steering systems

Tesla models Y and 3 are displayed at a Tesla dealership in Corte Madera, California, on Dec. 20, 2024.

Justin Sullivan | Getty Images

Tesla is voluntarily recalling 376,241vehicles in the U.S. to correct an issue with failing power-assisted steering systems, according to records posted to the website of the U.S. National Highway Traffic Safety Administration.

In a safety recall report posted on the NHTSA website, Tesla said the recall includes Model 3 and Model Y vehicles that were manufactured for sale in the U.S. from Feb. 28, 2023, to October 11, 2023, and that were equipped with a certain older software release.

The records said printed circuit boards in the steering systems in affected vehicles could become overstressed, causing the power-assist steering to fail in some cases when a Tesla vehicle rolled to a stop and then accelerated.

When electronic power-assist steering systems fail in a Tesla, drivers need to exert more force to steer their cars, which can increase the risk of a collision.

Read more CNBC tech news

Tesla told the vehicle safety regulator that it was not aware of any crashes, injuries or deaths related to the power steering failures, and that it was offering an over-the-air software update as a remedy.

The recall follows an earlier related probe and voluntary recall in China concerning the same systems.

President Donald Trump has appointed Tesla CEO Elon Musk to lead a team that is slashing the federal government workforce, and in some cases, regulations and entire agencies. Those cuts already affected the NHTSA, an agency Musk has long seen as standing in the way of some of his ambitions at Tesla.

The regulator has been engaged in a yearslong investigation into safety defects in the systems that Tesla markets currently as its Autopilot and Full Self-Driving (Supervised) options. The features do not make Tesla cars into robotaxis. They require a human driver ready to steer or brake at any time.

The Washington Post reported on Thursday that Musk’s team has led mass firings at the NHTSA, reducing the agency’s workforce and capacity to investigate companies including Tesla by about 10%.

Tesla didn’t respond to a request for comment.

WATCH: Tesla stock hinges on new vehicles being introduced

Tesla stock hinges on new vehicles being introduced, says Canaccord's  George Gianarikas

Continue Reading

Trending